Increased high-sensitivity C-reactive protein levels in Taiwanese schizophrenic patients

Asia-Pacific Psychiatry

Volumn 5, Issue 2, 2013, Pages

  Lin, Chin Chuen ^a   Chang, Chia Ming ^a   Liu, Chia Yih ^a   Huang, Tiao Lai ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Acute phase protein; Antipsychotics; C reactive protein; Schizophrenia

Indexed keywords

C REACTIVE PROTEIN; CLOZAPINE; OLANZAPINE; RISPERIDONE;

ADULT; AGE; ARTICLE; BODY MASS; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE DURATION; FEMALE; HUMAN; MALE; MENTAL PATIENT; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCHIZOPHRENIA;

ACUTE PHASE PROTEIN; ANTIPSYCHOTICS; C-REACTIVE PROTEIN; SCHIZOPHRENIA;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; SCHIZOPHRENIA;

EID: 84878198938     PISSN: 17585864     EISSN: 17585872     Source Type: Journal    
DOI: 10.1111/appy.12078     Document Type: Article

References (31)

1. Akanji A.O., Ohaeri J.U., Al-Shammri S., Fatania H.R. (2009) Association of blood levels of C-reactive protein with clinical phenotypes in Arab schizophrenic patients. Psychiatry Res. 169, 56-61.
2. Akiyama K. (1999) Serum levels of soluble IL-2 receptor alpha, IL-6 and IL-1 receptor antagonist in schizophrenia before and during neuroleptic administration. Schizophr Res. 37, 97-106.
3. American Psychiatric Association (2000) Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (Text Revision). American Psychiatric Publishing, Inc, Washington, DC.
4. An H.J., Jang J.W., Bae S.H., etal. (2012) Serum C-reactive protein is a useful biomarker to predict outcomes after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl. 18(12), 1406-1414.
5. Baptista T., Davila A., El Fakih Y., etal. (2007) Similar frequency of abnormal correlation between serum leptin levels and BMI before and after olanzapine treatment in schizophrenia. Int Clin Psychopharmacol. 22, 205-211.
6. Cantini F., Salvarani C., Olivieri I. (1998) Erythrocyte sedimentation rate and C-reactive protein in the diagnosis of polymyalgia rheumatica. Ann Intern Med. 128, 873-874.
7. Carrizo E., Fernandez V., Quintero J., etal. (2008) Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives. Schizophr Res. 103(1-3), 83-93.
8. Dickerson F., Stallings C., Origoni A., Boronow J., Yolken R. (2007) C-reactive protein is associated with the severity of cognitive impairment but not of psychiatric symptoms in individuals with schizophrenia. Schizophr Res. 93(1-3), 261-265.
9. Fan X., Pristach C., Liu E.Y., Freudenreich O., Henderson D.C., Goff D.C. (2007) Elevated serum levels of C-reactive protein are associated with more severe psychopathology in a subgroup of patients with schizophrenia. Psychiatry Res. 149(1-3), 267-271.
10. Fernandez-Egea E., Bernardo M., Donner T., etal. (2009) Metabolic profile of antipsychotic-naive individuals with non-affective psychosis. Br J Psychiatry. 194, 434-438.
11. Firooz N., Albert D.A., Wallace D.J., Ishimori M., Berel D., Weisman M.H. (2011) High-sensitivity C-reactive protein and erythrocyte sedimentation rate in systemic lupus erythematosus. Lupus. 20, 588-597.
12. Ford E.S. (1999) Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care. 22, 1971-1977.
13. Garcia-Miss Mdel R., Perez-Mutul J., Lopez-Canul B., etal. (2010) Folate, homocysteine, interleukin-6, and tumor necrosis factor alfa levels, but not the methylenetetrahydrofolate reductase C677T polymorphism, are risk factors for schizophrenia. J Psychiatr Res. 44, 441-446.
14. Hope S., Melle I., Aukrust P., etal. (2009) Similar immune profile in bipolar disorder and schizophrenia: selective increase in soluble tumor necrosis factor receptor I and von Willebrand factor. Bipolar Disord. 11, 726-734.
15. Huang T.L. (2002) Decreased serum albumin levels in Taiwanese patients with schizophrenia. Psychiatry Clin Neurosci. 56, 627-630.
16. Kermani T.A., Schmidt J., Crowson C.S., etal. (2012) Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis. Semin Arthritis Rheum. 41, 866-871.
17. Kim H.A., Jeon J.Y., An J.M., Koh B.R., Suh C.H. (2012) C-reactive protein is a more sensitive and specific marker for diagnosing bacterial infections in systemic lupus erythematosus compared to S100A8/A9 and procalcitonin. J Rheumatol. 39, 728-734.
18. Kim Y.K., Myint A.M., Verkerk R., Scharpe S., Steinbusch H., Leonard B. (2009) Cytokine changes and tryptophan metabolites in medication-naive and medication-free schizophrenic patients. Neuropsychobiology. 59, 123-129.
19. Loffler S., Loffler-Ensgraber M., Fehsel K., Klimke A. (2010) Clozapine therapy raises serum concentrations of high sensitive C-reactive protein in schizophrenic patients. Int Clin Psychopharmacol. 25, 101-106.
20. Maes M., Bosmans E., Kenis G., De Jong R., Smith R.S., Meltzer H.Y. (1997a) In vivo immunomodulatory effects of clozapine in schizophrenia. Schizophr Res. 26(2-3), 221-225.
21. Maes M., Delange J., Ranjan R., etal. (1997b) Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res. 66(1), 1-11.
22. Meyer J.M., McEvoy J.P., Davis V.G., etal. (2009) Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study. Biol Psychiatry. 66, 1013-1022.
23. Na K.S., Kim Y.K. (2007) Monocytic, Th1 and th2 cytokine alterations in the pathophysiology of schizophrenia. Neuropsychobiology. 56(2-3), 55-63.
24. Roberts W.L., Sedrick R., Moulton L., Spencer A., Rifai N. (2000) Evaluation of four automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Clin Chem. 46, 461-468.
25. Sugino H., Futamura T., Mitsumoto Y., Maeda K., Marunaka Y. (2009) Atypical antipsychotics suppress production of proinflammatory cytokines and up-regulate interleukin-10 in lipopolysaccharide-treated mice. Prog Neuropsychopharmacol Biol Psychiatry. 33, 303-307.
26. Visser M., Bouter L.M., McQuillan G.M., Wener M.H., Harris T.B. (1999) Elevated C-reactive protein levels in overweight and obese adults. JAMA. 282, 2131-2135.
27. Volanakis J.E. (2001) Human C-reactive protein: expression, structure, and function. Mol Immunol. 38(2-3), 189-197.
28. Wong C.T., Tsoi W.F., Saha N. (1996) Acute phase proteins in male Chinese schizophrenic patients in Singapore. Schizophr Res. 22, 165-171.
29. Zahlten-Hinguranage A., Goldschmidt H., Cremer F.W., etal. (2006) Preoperative elevation of serum C-reactive protein is predictive for prognosis in myeloma bone disease after surgery. Br J Cancer. 95, 782-787.
30. Zebrack J.S., Muhlestein J.B., Horne B.D., Anderson J.L., Intermountain Heart Collaboration Study G. (2002) C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina. J Am Coll Cardiol. 39, 632-637.
31. Zhang X.Y., Zhou D.F., Cao L.Y., Wu G.Y., Shen Y.C. (2005) Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics. Neuropsychopharmacology. 30, 1532-1538.